If current trends continue, the study projects a doubling of herpes zoster ophthalmicus hospitalizations by 2040.
Graefe's Archive for Clinical and Experimental Ophthalmology · 5 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
If current trends continue, the study projects a doubling of herpes zoster ophthalmicus hospitalizations by 2040.
The study characterized patients by sex, age, year, and treatment site (dermatology, ophthalmology, or both). The central finding was a 200% overall increase in patients, with an approximately eightfold increase in herpes zoster ophthalmicus inpatients. This rise was significant across all age groups, particularly in the 60-79 age group, which was most affected. Based on linear regression, the authors project that herpes zoster ophthalmicus cases could double by 2040 if trends persist. The findings imply a growing burden on inpatient ophthalmological care, which could be impacted by herpes zoster vaccination uptake.